Hansa Biopharma has hit a setback in its efforts to expand imlifidase beyond kidney transplantation.
Just three months after reporting a successful phase 3 trial in kidney transplant patients—a result that could support a first-ever U.S. approval—the Swedish biotech has failed to meet expectations in a separate late-stage study.
This time, the target was anti-glomerular basement membrane (anti-GBM) disease, a rare and severe autoimmune condition.
What the GOOD-IDES-02 Trial Showed?
In the phase 3 GOOD-IDES-02 study, Hansa evaluated imlifidase followed by standard of care versus standard of care alone.
Key findings at six months:
- Around 60% of patients treated with imlifidase plus standard care did not require dialysis
- However, patients receiving standard care alone showed a similar response
- As a result, the trial did not demonstrate superiority over the control arm
Standard care in the study included:
- Intensive plasma exchange (PLEX)
- Cyclophosphamide (CYC)
- Glucocorticoids
While the imlifidase arm showed meaningful biological activity, it failed to translate into a statistically significant clinical advantage.
Why the Results Fell Short?
According to Hansa, the outcome reflects how much treatment outcomes for anti-GBM disease have improved over time.
Historically:
- Only 20% to 25% of anti-GBM patients were dialysis-free at six months
- The 60% rate seen with imlifidase would have looked dramatic against older benchmarks
But in GOOD-IDES-02, standard care alone performed much better than expected, narrowing the gap.
“This suggests standard of care has improved significantly since earlier studies,” analysts at Redeye noted, calling the result a “moderate setback.”
Hansa’s Response to the Disappointment
Hansa CEO Renée Aguiar-Lucander acknowledged the miss but highlighted the positives.
“We are disappointed not to be able to provide a new treatment option for this patient group,” she said. “Despite deep and rapid reduction of anti-GBM antibodies, it did not result in a statistically significant outcome.”
Still, she emphasized that the dialysis-free rate in treated patients was almost three times higher than what is typically reported in older datasets.
Commercial Impact: What Changes Now?
The trial outcome dents imlifidase’s expansion potential. Redeye estimates:
- Peak sales in anti-GBM: ~$130 million
- Peak sales in kidney transplant: ~$450 million
With the anti-GBM indication now uncertain, imlifidase’s value proposition becomes more concentrated around transplantation.
The Bigger Picture
For Hansa Biopharma, the message is mixed:
- Strong momentum in kidney transplantation remains intact
- Expansion into anti-GBM disease has hit a wall
The results also highlight a broader trend in rare disease trials: improving standard of care can raise the bar so high that even biologically active drugs struggle to show incremental benefit.
For now, imlifidase’s future looks far brighter in transplant medicine than in autoimmune nephrology.
